Substandard/Counterfeit Antimicrobial Drugs

SUMMARY Substandard/counterfeit antimicrobial drugs are a growing global problem. The most common substandard/counterfeit antimicrobials include beta-lactams (among antibiotics) and chloroquine and artemisin derivatives (among antimalarials). The most common type of substandard/counterfeit antimicrobial drugs have a reduced amount of the active drug, and the majority of them are manufactured in Southeast Asia and Africa. Counterfeit antimicrobial drugs may cause increased mortality and morbidity and pose a danger to patients. Here we review the literature with regard to the issue of substandard/counterfeit antimicrobials and describe the prevalence of this problem, the different types of substandard/counterfeit antimicrobial drugs, and the consequences for the individuals and global public health. Local, national, and international initiatives are required to combat this very important public health issue.

[1]  I. Petralanda.  Quality of antimalarial drugs and resistance to Plasmodium vivax in Amazonian region , 1995, The Lancet.

[2]  M. ten Ham.  Health risks of counterfeit pharmaceuticals. , 2003, Drug safety.

[3]  Sergei G. Kazarian,et al.  Assessment of hand-held Raman instrumentation for in situ screening for potentially counterfeit artesunate antimalarial tablets by FT-Raman spectroscopy and direct ionization mass spectrometry. , 2008, Analytica chimica acta.

[4]  M. Boelaert,et al.  How better drugs could change kala‐azar control. Lessons from a cost‐effectiveness analysis , 2002, Tropical medicine & international health : TM & IH.

[5]  J. Zarocostas.  Refugees are often left out of AIDS plans, report says , 2004, The Lancet.

[6]  P. Ringwald,et al.  Chimiorésistance de P. falciparum en milieu urbain à Yaoundé, Cameroun. Part 1: S urveillance in vitro et in vivo de la résistance de Plasmodium falciparumà la chloroquine entre 1994 et 1999 à Yaoundé, Cameroun , 2000 .

[7]  M. Reidenberg,et al.  Counterfeit and substandard drugs , 2001, Clinical pharmacology and therapeutics.

[8]  S. E. Nsimba.  Problems associated with substandard and counterfeit drugs in developing countries: a review article on global implications of counterfeit drugs in the era of antiretroviral (ARVs) drugs in a free market economy. , 2009, East African journal of public health.

[9]  A. Wertheimer,et al.  Safeguarding against substandard/counterfeit drugs: mitigating a macroeconomic pandemic. , 2009, Research in social & administrative pharmacy : RSAP.

[10]  P. Ringwald,et al.  Chemoresistance of P. falciparum in urban areas of Yaounde, Cameroon. Part 1: Surveillance of in vitro and in vivo resistance of Plasmodium falciparum to chloroquine from 1994 to 1999 in Yaounde, Cameroon. , 2000, Tropical medicine & international health : TM & IH.

[11]  C. Rados.  FDA cautions against ultrasounds 'keepsake' images. , 2004, FDA consumer.

[12]  A. Rodomonte,et al.  "For export only" medicines come back to Europe: a RP-LC method for the screening of six glucocorticoids in illegal and counterfeit anti-inflammatory and lightening creams. , 2010, Journal of pharmaceutical and biomedical analysis.

[13]  J. Tuomilehto,et al.  Sodium excretion and cardiovascular mortality , 2001, The Lancet.

[14]  G. Tomson,et al.  Evaluation of the quality of amodiaquine and sulphadoxine/pyrimethamine tablets sold by private wholesale pharmacies in Dar Es Salaam Tanzania , 2003, Journal of clinical pharmacy and therapeutics.

[15]  J. Rozendaal.  Fake antimalaia drugs in Cambodia , 2001, The Lancet.

[16]  P. Brusa,et al.  Diffusion of counterfeit drugs in developing countries and stability of galenics stored for months under different conditions of temperature and relative humidity , 2012, Croatian medical journal.

[17]  I. Okeke,et al.  Quality and bioavailability of tetracycline capsules in a Nigerian semi-urban community. , 1995, International journal of antimicrobial agents.

[18]  H. Hogerzeil,et al.  Stability of essential drugs in Sudan , 1991, The Lancet.

[19]  D. Watson,et al.  The chemical and pharmaceutical equivalence of sulphadoxine/pyrimethamine tablets sold on the Tanzanian market , 2005, Journal of clinical pharmacy and therapeutics.

[20]  O. Shakoor,et al.  Assessment of the incidence of substandard drugs in developing countries , 1997, Tropical medicine & international health : TM & IH.

[21]  S. Sundar,et al.  A cluster of cases of severe cardiotoxicity among kala-azar patients treated with a high-osmolarity lot of sodium antimony gluconate. , 1998, The American journal of tropical medicine and hygiene.

[22]  O. Onwujekwe,et al.  Quality of anti-malarial drugs provided by public and private healthcare providers in south-east Nigeria , 2009, Malaria Journal.

[23]  R. Jähnke,et al.  Low-Cost Quality Assurance of Medicines Using the Gphf-Minilab® , 2001 .

[24]  Joseph Sherma,et al.  Counterfeit Drugs , 1927, The Indian medical gazette.

[25]  J. A. van Wyk,et al.  Quality control in generic anthelmintics: is it adequate? , 1997, Veterinary parasitology.

[26]  Liza Gibson.  Drug regulators study global treaty to tackle counterfeit drugs , 2004, BMJ : British Medical Journal.

[27]  P. Newton,et al.  Guidelines for Field Surveys of the Quality of Medicines: A Proposal , 2009, PLoS medicine.

[28]  L. Gostin,et al.  Countering the Problem of Falsified and Substandard Drugs , 2013 .

[29]  S. Pincock.  WHO tries to tackle problem of counterfeit medicines in Asia , 2003, BMJ : British Medical Journal.

[30]  A. Attaran,et al.  Antimalarial Drug Quality in the Most Severely Malarious Parts of Africa – A Six Country Study , 2008, PloS one.

[31]  J. Maurin,et al.  The usefulness of simple X-ray powder diffraction analysis for counterfeit control--the Viagra example. , 2007, Journal of pharmaceutical and biomedical analysis.

[32]  O. Müller,et al.  Substandard anti-malarial drugs in Burkina Faso , 2008, Malaria Journal.

[33]  M. Kron.  Substandard primaquine phosphate for US Peace Corps personnel , 1996, The Lancet.

[34]  Quality evaluation of chloroquine, quinine, sulfadoxine–pyrimethamine and proguanil formulations sold on the market in East Congo DR , 2007, Journal of clinical pharmacy and therapeutics.

[35]  R. B. Taylor,et al.  Substandard and Counterfeit Drugs in Developing Countries , 2002, Tropical doctor.

[36]  Kimberly Hess,et al.  Anti-malarial drug quality in Lagos and Accra - a comparison of various quality assessments , 2010, Malaria Journal.

[37]  C. Alm,et al.  Quality of chloroquine preparations marketed in Dar es Salaam, Tanzania , 1995, The Lancet.

[38]  W. J. Heath.  America's first drug regulation regime: the rise and fall of the Import Drug Act of 1848. , 2004, Food and drug law journal.

[39]  J. Plaizier-Vercammen,et al.  Quality control of active ingredients in artemisinin‐derivative antimalarials within Kenya and DR Congo , 2006, Tropical medicine & international health : TM & IH.

[40]  Y. D. Liu,et al.  Application of LC-NMR and LC-MS to the identification of degradation products of a protease inhibitor in dosage formulations. , 1999, Journal of pharmaceutical and biomedical analysis.

[41]  C. Dolea,et al.  World Health Organization , 1949, International Organization.

[42]  A. Obaid.  Quality of ceftriaxone in Pakistan: reality and resonance. , 2009, Pakistan journal of pharmaceutical sciences.

[43]  H. Wilde,et al.  Additional reports of failure to respond to treatment after rabies exposure in Thailand. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[44]  J. James.  Counterfit drugs: check Combivir, Serostim, Epogen. , 2002, AIDS treatment news.

[45]  A. W. Wan Po.  Too much, too little, or none at all: dealing with substandard and fake drugs. , 2001, Lancet.

[46]  M. Meadows.  Preventing serious drug interactions. , 2004, FDA consumer.

[47]  A. Po.  Too much, too little, or none at all: dealing with substandard and fake drugs , 2001, The Lancet.

[48]  P. Newton,et al.  Counterfeit artesunate antimalarials in southeast Asia , 2003, The Lancet.

[49]  S. Pandya,et al.  Letter from Bombay. An unmitigated tragedy. , 1988, BMJ.

[50]  M. Elamin,et al.  Quality of Antimalarial Drugs in Sudan: Results of Post-Marketing Surveillance , 2006 .

[51]  N. Day,et al.  A simple and rapid liquid chromatographic assay for evaluation of potentially counterfeit Tamiflu. , 2006, Journal of pharmaceutical and biomedical analysis.

[52]  Organización Mundial de la Salud.  Guidelines for the treatment of malaria , 2010 .

[53]  M. Lydecker,et al.  The Drug Swindlers , 1990, International journal of health services : planning, administration, evaluation.

[54]  S. P. Kachur,et al.  A Nationwide Survey of the Quality of Antimalarials in Retail Outlets in Tanzania , 2008, PloS one.

[55]  Si̇yaset Bi̇li̇mi̇.  National Agency for Food and Drug Administration and Control , 2011 .

[56]  G. Ellard.  The colorimetric analysis of anti-tuberculosis fixed-dose combination tablets and capsules. , 1999, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[57]  N. White,et al.  Delaying antimalarial drug resistance with combination chemotherapy. , 1999, Parassitologia.

[58]  D. Saville.  Influence of storage on in-vitro release of ibuprofen from sugar coated tablets. , 2001, International journal of pharmaceutics.

[59]  P. Hagan,et al.  Counterfeit praziquantel , 2001, The Lancet.

[60]  A. Prange.  What's in a pill? , 1969, Medical times.

[61]  S H Scafi,et al.  Identification of counterfeit drugs using near-infrared spectroscopy. , 2001, The Analyst.

[62]  B. Burton.  Australia's contribution to global health fund provokes dismay , 2004, BMJ : British Medical Journal.

[63]  S. Kyriacos,et al.  Quality of amoxicillin formulations in some Arab countries , 2008, Journal of clinical pharmacy and therapeutics.

[64]  M. Green,et al.  A colorimetric field method to assess the authenticity of drugs sold as the antimalarial artesunate. , 2000, Journal of pharmaceutical and biomedical analysis.

[65]  P. Ringwald,et al.  Randomised trial of pyronaridine versus chloroquine for acute uncomplicated falciparum malaria in Africa , 1996, The Lancet.

[66]  P. Ringwald,et al.  False chloroquine resistance in Africa , 1997, The Lancet.

[67]  T. Kenyon,et al.  Detection of substandard fixed-dose combination tuberculosis drugs using thin-layer chromatography. , 1999, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[68]  S. Hay,et al.  The global distribution of clinical episodes of Plasmodium falciparum malaria , 2005, Nature.

[69]  Jun Kawai,et al.  Analysis of wrapped or cased object by a hand-held X-ray fluorescence spectrometer. , 2005, Forensic science international.

[70]  L. Basco,et al.  Molecular epidemiology of malaria in Cameroon. XIX. Quality of antimalarial drugs used for self-medication. , 2004, The American journal of tropical medicine and hygiene.

[71]  R. A. Morrissey,et al.  Inadequate poliovirus immunity levels in immunized Illinois children. , 1973, American journal of diseases of children.

[72]  O. Shakoor,et al.  Pharmacopoeial quality of drugs supplied by Nigerian pharmacies , 2001, The Lancet.

[73]  K. Ahmad.  Antidepressants are sold as antiretrovirals in DR Congo , 2004, The Lancet.

[74]  A. Hussain,et al.  OFLOXACIN: LABORATORY EVALUATION OF THE ANTIBACTERIAL ACTIVITY OF 34 BRANDS REPRESENTING 31 MANUFACTURERS AVAILABLE IN PAKISTAN , 2004 .

[75]  Imti Choonara,et al.  Substandard and counterfeit medicines: a systematic review of the literature , 2013, BMJ Open.

[76]  J. Pandit,et al.  Effect of tablet disintegrants on the dissolution stability of nalidixic acid tablets , 1997 .

[77]  S O Alubo,et al.  Death for sale: a study of drug poisoning and deaths in Nigeria. , 1994, Social science & medicine.

[78]  A. Surendran.  World agencies try to stem flood of fake drugs , 2004, Nature Medicine.

[79]  A. Dayal,et al.  The need for better data about counterfeit drugs in developing countries: a proposed standard research methodology tested in Chennai, India , 2011, Journal of clinical pharmacy and therapeutics.

[80]  M. Mayxay,et al.  Fake antimalarials in Southeast Asia are a major impediment to malaria control: multinational cross‐sectional survey on the prevalence of fake antimalarials , 2004, Tropical medicine & international health : TM & IH.

[81]  J. Samet,et al.  Food and Drug Administration , 2007, BMJ : British Medical Journal.

[82]  I. Kibwage,et al.  Quality performance of metronidazole tablet products on the Kenyan market. , 1991, East African medical journal.

[83]  F. Ballereau,et al.  Quality Control of Antibiotics Before the Implementation of an STD Program in Northern Myanmar , 2002, Sexually transmitted diseases.

[84]  T. Kenyon,et al.  Substandard tuberculosis drugs on the global market and their simple detection. , 2001, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[85]  T. Land.  Combating counterfeit drugs , 1992, Nature.

[86]  M. Bennish,et al.  Fatal renal failure caused by diethylene glycol in paracetamol elixir : the Bangladesh epidemic , 2004 .

[87]  Counterfeiting: a global spread, a global threat , 2009 .

[88]  W. Herron,et al.  Development of a high-performance liquid chromatographic-mass spectrometric assay for the specific and sensitive quantification of Ro 64-0802, an anti-influenza drug, and its pro-drug, oseltamivir, in human and animal plasma and urine. , 2000, Journal of chromatography. B, Biomedical sciences and applications.

[89]  A. Carpentier,et al.  Update on counterfeit antibiotics worldwide; public health risks. , 2012, Medecine et maladies infectieuses.

[90]  B. Pécoul,et al.  Access to essential drugs in poor countries: a lost battle? , 1999, JAMA.

[91]  M. C. Moken.  Fake Pharmaceuticals: How They and Relevant Legislation or Lack Thereof Contribute to Consistently High and Increasing Drug Prices , 2003, American Journal of Law & Medicine.

[92]  I. Okeke,et al.  Quality and bioavailability of ampicillin capsules dispensed in a Nigerian semi-urban community. , 2001, African journal of medicine and medical sciences.

[93]  I. Ghebre-Sellassie,et al.  Current perspectives on the dissolution stability of solid oral dosage forms. , 1993, Journal of pharmaceutical sciences.

[94]  H. Frankish.  WHO steps up campaign on counterfeit drugs , 2003, The Lancet.

[95]  M. Issack.  Substandard drugs , 2001, The Lancet.

[96]  Thomas Layloff,et al.  The use of Minilabs to improve the testing capacity of regulatory authorities in resource limited settings: Tanzanian experience. , 2008, Health policy.

[97]  H. Atta,et al.  The quality of antimalarials available in Yemen , 2005, Malaria Journal.

[98]  A. Spake.  Fake drugs, real worries: high prices and the Internet are making U.S. patients easy prey. , 2004, U.S. news & world report.

[99]  Paul N Newton,et al.  Counterfeit anti-infective drugs. , 2006, The Lancet. Infectious diseases.

[100]  S. Chattopadhyay.  Access to essential drugs in poor countries. , 1999, JAMA.

[101]  J. Amon.  Dangerous medicines: Unproven AIDS cures and counterfeit antiretroviral drugs , 2008, Globalization and health.

[102]  M. Kolczak,et al.  Sulfadoxine-Pyrimethamine in Treatment of Malaria in Western Kenya: Increasing Resistance and Underdosing , 2003, Antimicrobial Agents and Chemotherapy.

[103]  Patrick Lukulay,et al.  Implementation of basic quality control tests for malaria medicines in Amazon Basin countries: results for the 2005–2010 period , 2012, Malaria Journal.

[104]  D. Socheat,et al.  Counterfeit and substandard antimalarial drugs in Cambodia. , 2006, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[105]  K. Krishnaswamy,et al.  Bioavailability of different brands of tetracycline in undernourished subjects. , 1992, International journal of clinical pharmacology, therapy, and toxicology.

[106]  R. B. Taylor,et al.  Drug quality, a contributor to drug resistance? , 1995, The Lancet.

[107]  A. Mcgregor.  WHO: Counterfeit pharmaceuticals , 1992, The Lancet.

[108]  M. Forzley.  Combating counterfeit drugs: a concept paper for effective international collaboration , 2005 .

[109]  L. Mooney,et al.  Substandard and Falsified Anti-Tuberculosis Drugs: A Preliminary Field Analysis , 2012, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[110]  R. Panchagnula,et al.  In vitro evaluation of fixed dose combination tablets of anti-tuberculosis drugs after real time storage at ambient conditions. , 2004, Die Pharmazie.

[111]  T. Parfitt.  Russia cracks down on counterfeit drugs , 2006, The Lancet.

[112]  W. Wernsdorfer.  Epidemiology of drug resistance in malaria. , 1994, Acta tropica.

[113]  R. Wirtz,et al.  Determination of Oseltamivir Quality by Colorimetric and Liquid Chromatographic Methods , 2008, Emerging infectious diseases.

[114]  William Burns,et al.  WHO launches taskforce to fight counterfeit drugs. , 2006, Bulletin of the World Health Organization.

[115]  Stephane Proux,et al.  Fake artesunate in southeast Asia , 2001, The Lancet.

[116]  J. Remon,et al.  In vitro evaluation of the quality of essential drugs on the Tanzanian market , 2002, Tropical medicine & international health : TM & IH.

[117]  P. Newton,et al.  Manslaughter by Fake Artesunate in Asia—Will Africa Be Next? , 2006, PLoS medicine.

[118]  K. Barnes,et al.  Antimalarial dosing regimens and drug resistance. , 2008, Trends in parasitology.

[119]  H. McIlleron,et al.  Recent bioequivalence studies on fixed-dose combination anti-tuberculosis drug formulations available on the global market. , 1999, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[120]  B. Lindgren,et al.  The quality of drugs in private pharmacies in Lao PDR: a repeat study in 1997 and 1999 , 2004, Pharmacy World and Science.

[121]  R. Panchagnula,et al.  Quality control of anti-tuberculosis FDC formulations in the global market: part II-accelerated stability studies. , 2005, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[122]  L. Salako,et al.  Bioavailability of sulphate and dihydrochloride salts of quinine. , 1994, African journal of medicine and medical sciences.

[123]  M. Moshi,et al.  Comparative Bioavailability of Oral Sugar-Coated and Plain Formulation of Chloroquine Phosphate Marketed in Tanzania , 2002, Tropical doctor.

[124]  R. Cody,et al.  Versatile new ion source for the analysis of materials in open air under ambient conditions. , 2005, Analytical chemistry.

[125]  D. Menkes,et al.  Hazardous drugs in developing countries , 1997, BMJ.

[126]  Shiji Zhou,et al.  Establishment of a Fast Chemical Identification System for screening of counterfeit drugs of macrolide antibiotics. , 2006, Journal of pharmaceutical and biomedical analysis.

[127]  J. Remon,et al.  The quality of essential antimicrobial and antimalarial drugs marketed in Rwanda and Tanzania: influence of tropical storage conditions on in vitro dissolution , 2004, Journal of clinical pharmacy and therapeutics.

[128]  Christina Y Hampton,et al.  A Collaborative Epidemiological Investigation into the Criminal Fake Artesunate Trade in South East Asia , 2008, PLoS medicine.

[129]  M. ten Ham.  Counterfeit drugs: implications for health. , 1992, Adverse drug reactions and toxicological reviews.

[130]  A. Attaran,et al.  Pilot Study of Essential Drug Quality in Two Major Cities in India , 2009, PloS one.

[131]  I. Okeke,et al.  Socioeconomic and behavioral factors leading to acquired bacterial resistance to antibiotics in developing countries. , 1999, Emerging infectious diseases.

[132]  J. O. Lawson,et al.  Diethylene glycol poisoning in Nigerian children. , 1992, Annals of tropical paediatrics.

[133]  P. Newton,et al.  Characterization of Solid Counterfeit Drug Samples by Desorption Electrospray Ionization and Direct‐analysis‐in‐real‐time Coupled to Time‐of‐flight Mass Spectrometry , 2006, ChemMedChem.

[134]  H. Masur,et al.  Analysis of generic nevirapine products in developing countries. , 2003, JAMA.

[135]  K. J. Mulligan,et al.  Analysis of organic volatile impurities as a forensic tool for the examination of bulk pharmaceuticals. , 1996, Journal of chromatography. B, Biomedical applications.

[136]  I. Gyssens,et al.  Cross-sectional study of availability and pharmaceutical quality of antibiotics requested with or without prescription (Over The Counter) in Surabaya, Indonesia , 2010, BMC infectious diseases.

[137]  L. Valvo,et al.  Development and validation of a reversed-phase LC method for analysing potentially counterfeit antimalarial medicines. , 2006, Journal of pharmaceutical and biomedical analysis.

[138]  S. Arya.  Inadvertent supply of substandard drugs. , 1995, World health forum.

[139]  Kenneth J Rothman,et al.  Fake antimalaria drugs in Cambodia. , 2001, Lancet.

[140]  P. Newton,et al.  Murder by fake drugs , 2002, British medical journal.

[141]  张静,et al.  Banana Ovate family protein MaOFP1 and MADS-box protein MuMADS1 antagonistically regulated banana fruit ripening , 2015 .

[142]  M. Green.  Antimalarial drug resistance and the importance of drug quality monitoring. , 2006, Journal of Postgraduate Medicine.

[143]  F. Gimenez,et al.  Etude de la qualité des médicaments vendus et dispensés au Cambodge , 1997 .

[144]  I. Kibwage,et al.  Sulphadoxinel/pyrimethamine tablet products on the Kenyan market: Quality Concerns , 2000 .

[145]  T. R. D. Wit,et al.  Global threat from drug resistant HIV in sub-Saharan Africa , 2012, BMJ : British Medical Journal.

[146]  R. Snow,et al.  The quality of sulphadoxine‐pyrimethamine and amodiaquine products in the Kenyan retail sector , 2005, Journal of clinical pharmacy and therapeutics.

[147]  S. Houston.  Justice and HIV Care in Africa—Antiretrovirals in Perspective , 2002, Journal of the International Association of Physicians in AIDS Care.

[148]  B. Lindgren,et al.  The quality of drugs in private pharmacies in the Lao People’s Democratic Republic , 1998 .

[149]  P. Newton,et al.  How to achieve international action on falsified and substandard medicines , 2012, BMJ : British Medical Journal.

[150]  R. Laing,et al.  Quality and stability of TB medicines: let the buyer beware! , 2004, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[151]  D. Okello,et al.  Quality of oral and parenteral chloroquine in Kampala. , 1998, East African medical journal.

[152]  Paul N. Newton,et al.  The Global Threat of Counterfeit Drugs: Why Industry and Governments Must Communicate the Dangers , 2005, PLoS Medicine.

[153]  R. Cooks,et al.  Mass Spectrometry Sampling Under Ambient Conditions with Desorption Electrospray Ionization , 2004, Science.

[154]  Marya Lieberman,et al.  Paper analytical devices for fast field screening of beta lactam antibiotics and antituberculosis pharmaceuticals. , 2013, Analytical chemistry.

[155]  Protecting consumers from counterfeit drugs. , 2004, FDA consumer.

[156]  P. Sriskandabalan,et al.  Self-medication with zidovudine that was not , 2001, The Lancet.

[157]  Arya Sc.  Inadvertent supply of substandard drugs. , 1995 .

[158]  Michael Jones.  Gains and Losses for Tropical Doctor , 2002 .

[159]  H. Hogerzeil,et al.  The quality and stability of essential drugs in rural Zimbabwe: controlled longitudinal study , 1998, BMJ.

[160]  F. Ballereau,et al.  Stability of essential drugs in the field: results of a study conducted over a two-year period in Burkina Faso. , 1997, The American journal of tropical medicine and hygiene.

[161]  O. Tomori,et al.  Evaluation of measles vaccination programme conducted in two separate health centres. , 1992, Vaccine.

[162]  C. Obua,et al.  Chloroquine in the Ugandan market fails quality test: a pharmacovigilance study. , 2003, African health sciences.

[163]  T. Lancet.  Quality control and essential drugs , 1997, The Lancet.

[164]  J. Roy.  The menace of substandard drugs. , 1994, World health forum.

[165]  Matthew E Falagas,et al.  Counterfeit or substandard antimicrobial drugs: a review of the scientific evidence. , 2007, The Journal of antimicrobial chemotherapy.

[166]  O. Adegoke,et al.  Pharmaceutical Equivalence of Some Commercial Samples of Artesunate and Amodiaquine Tablets Sold in Southwestern Nigeria , 2010 .

[167]  J. Wolff,et al.  Identification of the 'wrong' active pharmaceutical ingredient in a counterfeit Halfan drug product using accurate mass electrospray ionisation mass spectrometry, accurate mass tandem mass spectrometry and liquid chromatography/mass spectrometry. , 2003, Rapid communications in mass spectrometry : RCM.